Search clinical trials for: TQ-B3139

Total 69 results

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics

Advanced Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Effect of High-fat Meal on the Pharmacokinetics of TQ-B3139 Capsules

Advanced Solid Tumors

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

ALK-positive NSCLC

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

ALK-positive NSCLC

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects

Hepatitis B

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL）

Peripheral T-cell Lymphoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Phase I Study of TQ-B3101 on Tolerance and Pharmacokinetics

Advanced Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics

Advanced Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQ-B3525 on Tolerance and Pharmacokinetics

Relapsed or Refractory Lymphoma or Advanced Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Pharmacokinetic Study of TQB3101 in Chinese Healthy Subjects

Pharmacokinetic Study

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor

Advanced Malignant Tumor

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Phase I Study of TQ-B3234 on Tolerance and Pharmacokinetics

Advanced Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Material Balance Study of TQ-B3525

Chronic Kidney Diseases | Magnetic Resonance Imaging

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)

Relapsed / Refractory Mantle Cell Lymphoma (MCL)

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)

Relapsed / Refractory Follicular Lymphoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Tolerance and Pharmacokinetics of TQ-B3233

Tumor

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A New Drug Used for Advanced Cancer

Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Pharmacokinetic and Tolerance Study of TQ-A3326 in Healthy Participants.

Pharmacokinetic

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL）

Diffuse Large B-cell Lymphoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL)

Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL)

China
Tongji Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study) (Neptune)

Chronic Hepatitis b
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors

Advanced Endometrial Cancer, Cervical Cancer and Ovarian Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Terminated

A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

China
Novatek Pharmaceuticals

Recruiting

Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive. (BOSS-002)

COVID-19

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQ-B3234 in Patients With Type I Neurofibromatosis

Type I Neurofibromatosis

China
Genta Incorporated

Terminated

Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment

Advanced Melanoma and Normal or Impaired | Hepatic Function
Genta Incorporated

Completed

Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function

Normal Renal Function | Mildly Impaired Renal Function | Moderately Impaired Renal Function

United States
National Cancer Institute (NCI)

Completed

Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

Waldenström Macroglobulinemia

United States
King Abdulaziz University

Not yet recruiting

The Assessment of Clinical Efficacy of Topical Application of 5% Thymoquinone Gel for Gingivitis Patients

Gingivitis

Saudi Arabia
Novatek Pharmaceuticals

Completed

To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants (BOSS)

Covid19

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets

Non-small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B

Chronic Hepatitis B

China
Naval Medical Research Center
The 108 Military Central Hospital; Naval Medical Research Unit TWO (NAMRU-2); Australian Defence Force Malaria and Infectious Disease Institute (ADF MIDI) and other collaborators

Not yet recruiting

Escalating Monthly Doses of Tafenoquine in Healthy Volunteers (TQ)

Prophylaxis

Vietnam
National Cancer Institute (NCI)

Completed

Oblimersen in Treating Patients With Merkel Cell Carcinoma

Recurrent Neuroendocrine Carcinoma of the Skin | Stage III Neuroendocrine Carcinoma of the Skin | Stage IV Neuroendocrine Carcinoma of the Skin | Stage II Neuroendocrine Carcinoma of the Skin | Stage I Neuroendocrine Carcinoma of the Skin

United States
Uniformed Services University of the Health Sciences

Completed

LAVA TQ Doppler Functionality Study

Traumatic Hemorrhage

United States
Genta Incorporated

Completed

Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | CLL

United States
Genta Incorporated

Withdrawn

This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)

Lymphocytic Leukemia
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer

Nonsmall-cell Lung Cancer

China
Genta Incorporated

Completed

A Phase I Study of G3139 Subcutaneous in Solid Tumors

Tumors

United States
National Cancer Institute (NCI)

Terminated

Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery

Gastrointestinal Stromal Tumor

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.

HER2-positive Metastatic Breast Cancer

China
National Cancer Institute (NCI)

Completed

Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
National Cancer Institute (NCI)

Terminated

Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Terminated

Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

Stage III Grade 1 Follicular Lymphoma | Stage III Grade 2 Follicular Lymphoma | Stage III Grade 3 Follicular Lymphoma | Stage IV Grade 1 Follicular Lymphoma | Stage IV Grade 2 Follicular Lymphoma | Stage IV Grade 3 Follicular Lymphoma

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

China
National Cancer Institute (NCI)

Terminated

A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer

Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Squamous Cell Carcinoma of the Esophagus | Adenocarcinoma of the Esophagus | Recurrent Esophageal Cancer | Stage IV Esophageal Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma... and other conditions

United States
Genta Incorporated

Completed

Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors

Solid Tumors

United States

Search clinical trials for: TQ-B3139

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations